- Global Pharma News & Resources

Peptide And Anticoagulant Drugs Market Set for Lucrative Growth, To Reach Around USD 1,860 Million By 2025

Zion Market Research has published a new report titled “Peptide and Anticoagulant Drugs Market by Type (Antifungal, Hormonal, Ace Inhibitors, Antibiotic, and Other Drugs), by Low Molecular Weight Heparin Type (Heparin Sodium, Enoxaparin Sodium, Dalteparin Sodium, and Fondaparinux), and by Application (Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global peptide and anticoagulant drugs market was approximately USD 1,363 million in 2018 and is expected to generate around USD 1,860 million by 2025, at a CAGR of around 4.6% between 2019 and 2025.

Anticoagulants drugs are referred to as blood thinners. It is a form of chemical substance that prevents the delay in clotting time and helps to keep the affected area unclotted for a longer time period. These drugs are specially used for treating diseases like pulmonary embolism, deep vein thrombosis, stroke, myocardial infarction, and others. Anticoagulant drugs have a wide range of applications that play an important role in terms of providing treatment for several diseases like cardiovascular, osteoporosis, cancer, diabetes, and coagulation disorders. Thus, these drugs act as a prevention measure for treating serious diseases. The oral anticoagulant drug is newly introduced in the market in the form of pills, to help prevent the blood clotting in the vital organs. Peptide drugs are drugs that act as hormones. These molecules are universally called proteins and carry a long chain of amino acids, whose key functions are recognized on the basis of amino acid size and sequence.

The global peptide and anticoagulant drugs market is likely to showcase significant growth in the future, due to the increasing prevalence of chronic diseases like cancer, osteoporosis, diabetes, and coagulation disorders, growing healthcare expenditure, rising global population, and increasing number of government initiatives to support pharmaceutical companies. The growing awareness among individuals about the benefits of early tests is also contributing toward the expansion of the peptide and anticoagulant drugs market globally. However, the availability of alternative drugs may be a major restraint in the peptide and anticoagulant drugs market growth.

Get Sample of this Research Report

The peptide and anticoagulant drugs market is classified on the basis of type, Low molecular weight Heparin type, and application. On the basis of type, the market includes antibiotic, antifungal, hormonal, ace inhibitors, and other drugs. The hormonal segment is likely to lead the Indian peptide drugs market, in terms of revenue, owing to the increasing diabetes occurrence and rising global population.

Based on low molecular weight Heparin type, the market is categorized into Dalteparin sodium, Fondaparinux, heparin sodium, and enoxaparin sodium. Enoxaparin sodium accounts for the largest share and dominates the market in terms of revenue.

Based on application, the market includes gynecology, osteoporosis, infectious diseases, cancer, cardiology, diabetes, and others. Diabetes is dominating the market with the highest revenue share, due to the increasing number of diabetic patients across the globe.

North America dominates the peptide and anticoagulant drugs market with the largest revenue share, due to the growing inventions in clinical practice, rising access to cancer treatment, especially breast cancer, and cancer research. Europe held the second largest revenue share in 2018 of the peptide and anticoagulant drugs market, due to the increasing use of tobacco. The Asia Pacific peptide and anticoagulant drugs market will register the highest CAGR over the forecast time period, owing to the increasing incidences of cancer, metabolic disorders, and hepatitis and various developments witnessed in peptide synthesis technology.

Some key players operating in the peptide and anticoagulant drugs market are Sun Pharmaceutical Industries, Baxter, HemmoPharma, Celsus, Wockhardt, AmbioPharm, Biofer, Bachem, Pfizer, Abbott Laboratories, Aspen, Eli Lilly, Takeda, Teva, Sanofi, and Novo Nordisk.

Browse TOC for more Insights

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 12-Aug-2020